Megan Majocha, PhD
@meganmajocha.bsky.social did:plc:npimk377dmsrupl7emrwkqar
Scientific Communications Manager @ Susan G. Komen | Breast Cancer Metastasis Researcher | Dog Mom
No Bluesky desde
- Seguidores
- 34
- Seguindo
- 62
- Posts
- 1
- Dias nos rankings
- 0
Resumo
Megan Majocha, PhD (@meganmajocha.bsky.social) é um usuário do Bluesky desde 25 fevereiro 2025. Tem 34 seguidores, segue 62 contas e publicou 1 posts.
Aparições nos rankings
Os melhores dias em que posts desta conta entraram na lista diária do Debya.
Esta conta ainda não apareceu em um ranking diário.
Posts curtidos recentemente
Curtidas públicas da rede Bluesky.
Phase 3 KEYNOTE-522 final results 👀💥 Javier Cortes, MD, PhD presents data from the trial evaluating pembrolizumab + chemo before surgery, followed by adjuvant pembrolizumab vs placebo. #ASCO26 @ascocancer.bsky.social
Ver postCan some people safely avoid chemo in higher-risk early breast cancer? 🤔 OPTIMA phase 3 tests a genomic-guided strategy vs standard of care in HR+/HER2- #breastcancer. Robert Stein, PhD presents first results at #ASCO26 @ascocancer.bsky.social
Ver postNew biomarker insights from NATALEE trial presented by Stephen Chia, MD 📊 Baseline gene expression shows prognostic & predictive impact in HR+/HER2- early #breastcancer treated with adjuvant ribociclib + aromatase inhibitor #ASCO26 @ascocancer.bsky.social
Ver postRecurrence remains a challenge in HR+/HER2- early #breastcancer. Phase 3 lidERA trial previously showed improvement with giredestrant (oral SERD) vs standard hormone therapy 📈 Peter Schmid, MD, PhD presents results by menopausal status at #ASCO26 @ascocancer.bsky.social
Ver post🚀 At #SABCS25, Ben Park, MD, PhD showed how cell signals go "off the rails" in breast cancer and how his groundbreaking work with cfDNA is changing care by helping earlier detection, better treatment tracking, and spotting metastasis sooner. @sabcs.bsky.social
Ver post
Contas que bloqueia
No Bluesky, bloqueios são registros públicos.
Esta conta não bloqueia ninguém.